BBB penetrating drugs market is projected to grow at an annualized rate of ~154%

Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Key Market Insights

§  More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are 35+ technology platforms for the development of BBB penetrant drugs

§  Majority of drug candidates are currently in the early stages of development, and are intended for the treatment of neurological conditions; a large proportion of the existing pipeline molecules are biologics

§  In order to achieve a competitive edge, several technology developers are presently focusing on the integration of advanced technical features into their proprietary drug development / delivery platforms

§  An assessment of 240+ drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed that many such firms are likely to partner with technology providers in order to leverage their BBB penetration expertise

§  Over the years, more than 16,700 patents related to BBB technologies have been filed / granted to various industry and non-industry players, indicating the pace of R&D activity in this burgeoning field of research

§  Foreseeing a lucrative future, several private and public investors have invested close to USD 1 billion, across more than 70 funding instances

§  Revenues generated from the sales of BBB penetrating drugs are anticipated to be well distributed across different types of molecules, target disease indications and various global regions over time

§  In the near-term, the opportunity is likely to be driven by licensing activity driven by the capability of leading BBB penetrating technologies to successfully facilitate drug delivery into the brain

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Table of Contents

 

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

 

2. EXECUTIVE SUMMARY

 

3. INTRODUCTION

3.1. Chapter Overview

3.2. Structure of the Human Brain

3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)

 

3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)

3.4.1. Invasive Techniques

3.4.1.1. Systemic Administration of Therapeutics

3.4.1.2. Direct Administration of Therapeutics

3.4.1.3. Intracerebral Devices and Implants

 

3.4.2. Non-Invasive Techniques / Approaches

3.4.2.1. Liposomes

3.4.2.2. Exosomes

3.4.2.3. Prodrugs

3.4.2.4. Nanoparticles and Microspheres

3.4.2.5. Novel Formulations and Conjugates

3.4.3. Chemical Delivery Systems

 

3.5. Blood-Brain Barrier (BBB)

3.5.1. Key Historical Milestones

3.5.2. Structure and Key Components

3.5.3. Key Functions

 

3.6. Strategies for Drug Delivery across the BBB

3.6.1. Increasing Permeability by Temporary Disruption of the BBB

3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB

3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery

 

3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies

3.8.1. Emerging Focus Areas

3.8.2. Key Historical Trends

3.8.3. Geographical Activity

3.9. Concluding Remarks

 

4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION

4.1. Chapter Overview

4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape

4.2.1. Analysis by Status of Development

4.2.2. Analysis by Underlying Principle

4.2.3. Analysis by Compatible Pharmacological Molecule(s)

4.2.4. Analysis by Target Receptor(s)

4.2.5. Analysis by Target Disease Indication(s)

4.2.6. Analysis by Patent Availability

4.2.7. Analysis by Licensing Activity

 

4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters

 

5. MARKET LANDSCAPE: BBB PENETRATING DRUGS

5.1. Chapter Overview

5.2. BBB Penetrating Drugs: Development Pipeline

5.2.1. Analysis by Phase of Development

5.2.2. Analysis by Type of Molecule

5.2.3. Analysis by Affiliated BBB Penetration Technology

5.2.4. Analysis by Route of Administration

5.2.5. Analysis by Target Disease Indication(s)

5.2.6. Analysis by Therapeutic Area(s)

5.3. BBB Penetrating Drugs: Additional Information

 

5.4. BBB Penetrating Drug Developers: Overall Market Landscape

5.4.1. Analysis by Year of Establishment

5.4.2. Analysis by Company Size

5.4.3. Analysis by Location of Headquarters

5.4.4. Leading Drug Developers: Analysis by Number of Drugs

5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size

5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications

5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company

 

6. COMPANY PROFILES

6.1. Chapter Overview

6.2. Leading Players based in North America

 

6.2.1. Angiochem

6.2.1.1. Company Overview

6.2.1.2. Technology Overview

6.2.1.3. Product Portfolio

6.2.1.4. Recent Developments and Future Outlook

 

6.2.2. ArmaGen

6.2.2.1. Company Overview

6.2.2.2. Technology Overview

6.2.2.3. Product Portfolio

6.2.2.4. Recent Developments and Future Outlook

 

6.2.3. Denali Therapeutics

6.2.3.1. Company Overview

6.2.3.2. Technology Overview

6.2.3.3. Product Portfolio

6.2.3.4. Recent Developments and Future Outlook

 

6.2.4. ICB International

6.2.4.1. Company Overview

6.2.4.2. Technology Overview

6.5.4.3. Product Portfolio

6.2.4.4. Recent Developments and Future Outlook

 

6.2.5. Lauren Sciences

6.2.5.1. Company Overview

6.2.5.2. Technology Overview

6.2.5.3. Product Portfolio

6.2.5.4. Recent Developments and Future Outlook

 

6.3. Leading Players based in Europe

6.3.1. BioArctic

6.3.1.1. Company Overview

6.3.1.2. Technology Overview

6.3.1.3. Product Portfolio

6.3.1.4. Recent Developments and Future Outlook

 

6.3.2. Cyclenium Pharma

6.3.2.1. Company Overview

6.3.2.2. Technology Overview

6.3.2.3. Product Portfolio

6.3.2.4. Recent Developments and Future Outlook

 

6.3.3. Iproteos

6.3.3.1. Company Overview

6.3.3.2. Technology Overview

6.3.3.3. Product Portfolio

6.3.3.4. Recent Developments and Future Outlook

 

6.3.4. Medesis Pharma

6.3.4.1. Company Overview

6.3.4.2. Technology Overview

6.3.4.3. Product Portfolio

6.3.4.4. Recent Developments and Future Outlook

 

6.3.5. Ossianix

6.3.5.1. Company Overview

6.3.5.2. Technology Overview

6.3.5.3. Product Portfolio

6.3.5.4. Recent Developments and Future Outlook

 

6.3.6. Vect-Horus

6.3.6.1. Company Overview

6.3.6.2. Technology Overview

6.3.6.3. Product Portfolio

6.3.6.4. Recent Developments and Future Outlook

 

6.4. Leading Players based in Asia-Pacific

6.4.1. JCR Pharmaceuticals

6.4.1.1. Company Overview

6.4.1.2. Technology Overview

6.4.1.3. Product Portfolio

6.4.1.4. Recent Developments and Future Outlook

 

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview

7.2. Methodology and Key Parameters

7.3. BBB Penetration Technologies: Platform Competitiveness Analysis

 

8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES

8.1. Chapter overview

8.2. Receptor Mediated Transcytosis (RMT)

8.2.1. Type of Target Receptors

8.2.1.1. Diphtheria Toxin Receptor

8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor

8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)

8.2.1.4. Transferrin Receptor

 

8.2.2. Types of RMT Approaches

8.2.2.1. Bispecific Antibody-based Approach

8.2.2.2. Molecular Trojan Horse-based Approach

8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses

8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)

8.2.2.2.3. Popular Conjugation Strategies

8.2.2.2.3.1. Direct Coupling Approach

8.2.2.2.3.2. Nanoparticles-based Approach

 

8.3. Increasing the Permeability of the BBB

8.3.1. Use of Ultrasound Waves

8.3.2. Use of High-Frequency Electric Field

 

8.4. Passive Diffusion

 

8.5. Novel Approaches

8.5.1. Cell Penetrating Peptides

8.5.2. Macrocycles

8.5.3. Organ-on-a-Chip Technology

 

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

 

9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Year and Type of Partnership

9.3.4. Analysis by Type of Partner

9.3.5. Analysis by Focus Area

9.3.6. Analysis by Type of Molecule

9.3.7. Analysis by Target Disease Indication

9.3.8. Most Active Players: Analysis by Number of Partnerships

9.3.9. Most Popular Technologies: Analysis by Number of Partnerships

9.3.10. Regional Analysis

9.3.11. Intercontinental and Intracontinental Agreements

 

10. ANALYSIS OF RECENT LICENSING AGREEMENTS

10.1. Chapter Overview

10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry

 

10.3. Types of Licensing Agreements

10.3.1. Out-Licensing Agreements

10.3.2. In-Licensing Agreements

 

10.4. Components of Licensing Agreements

 

10.5. Recent Examples of BBB-Related Technology Licensing Agreements

10.5.1. Analysis by Year of Agreement

10.5.2. Analysis by Type of Licensing Agreement

10.5.3. Analysis by Type of Owner

10.5.4. Most Active Players: Analysis by Number of Licensing Agreements

10.5.5. Most Popular Technologies: Analysis by Number of Licensing Agreements

10.5.6. Regional Analysis

10.5.7. Intercontinental and Intracontinental Licensing Agreements

 

10.6. Case-in-Point: Technology Licensing Timeline

10.6.1. Sumitomo Dainippon Pharma and JCR Pharmaceuticals

10.6.2. Denali Therapeutics and Sanofi

10.6.3. biOasis Technologies and Prothena

10.6.4. Vect-Horus and Janssen Pharmaceuticals

10.7. Concluding Remarks

 

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Chapter Overview

11.2. Types of Funding

11.3. Non-Invasive BBB Penetration Technologies and Drugs: List of Funding and Investments

11.3.1. Analysis by Number of Instances

11.3.2. Analysis by Amount Invested

11.3.3. Analysis by Type of Funding

11.3.4. Analysis by Type of Company

11.3.5. Analysis by Purpose of Funding

11.3.6. Analysis by Type of Molecule

11.3.7. Analysis by Target Disease Indication

11.3.8. Analysis by Geography

11.3.9. Most Active Players: Analysis by Number of Funding Instances

11.3.10. Most Popular Technologies: Analysis by Number of Funding Instances

11.3.11. Most Active Investors: Analysis by Number of Funding Instances

11.4. Concluding Remarks

 

12. PATENT ANALYSIS

12.1. Chapter Overview

12.2. Scope and Methodology

12.3. Non-Invasive BBB Penetration Technologies: Patent Analysis

12.3.1. Analysis by Application Year

12.3.1.1. Analysis by Filed Patent Applications

12.3.1.2. Analysis by Granted Patent Applications

 

12.3.2. Analysis by Issuing Authority / Patent Offices Involved

12.3.3. Analysis by CPC Symbols

12.3.4. Emerging Focus Areas

12.3.5. Analysis by Type of Organization

12.3.6. Leading Assignees: Analysis by Number of Patents

 

12.4. Non-Invasive BBB Technologies: Patent Valuation Analysis

 

13. DRUG DEVELOPMENT STRATEGY ANALYSIS

13.1. Chapter Overview

13.2 Scope and Methodology

13.3. Strategies Adopted by Late-Stage Drug Candidates

13.3.1. Drug A

13.3.2. Drug B

13.3.3. Drug C

13.3.4. Drug D

 

13.4. Concluding Remarks

 

14. MARKET POTENTIAL OF KEY NEUROLOGICAL DISORDERS

14.1. Chapter Overview

14.2. Market Potential of Key Neurological Disorders: 3D Bubble Chart Analysis

14.3. Key Neurological Disorders: Detailed Information

 

14.3.1. Alzheimer’s Disease

14.3.1.1. Disease Description

14.3.1.2. Epidemiology

14.3.1.3. Symptoms

14.3.1.4. Current Treatment Options

14.3.1.5. BBB Penetrating Drugs for Alzheimer’s Disease

14.3.1.6. Roots Analysis Perspective

 

14.3.2. Brain Cancer

14.3.2.1. Disease Description

14.3.2.2. Epidemiology

14.3.2.3. Symptoms

14.3.2.4. Current Treatment Options

14.3.2.4.1. Surgery

14.3.2.4.2. Radiation Therapy

14.3.2.4.3. Systemic Therapy

 

14.3.2.5. BBB Penetrating Drugs for Brain Cancer

14.3.2.6. Roots Analysis Perspective

 

14.3.3. Multiple Sclerosis

14.3.3.1. Disease Description

14.3.3.2. Epidemiology

14.3.3.3. Symptoms

14.3.3.4. Current Treatment Options

14.3.3.4.1. Treatment for Attacks

14.3.3.4.2. Treatments to Modify Progression

14.3.3.4.3. Interferons

14.3.3.5. BBB Penetrating Drugs for Multiple Sclerosis

14.3.3.6. Roots Analysis Perspective

 

14.3.4. Parkinson’s Disease

14.3.4.1. Disease Description

14.3.4.2. Epidemiology

14.3.4.3. Symptoms

14.3.4.4. Current Treatment Options

14.3.4.4.1. Pharmacological Management of Parkinson’s Disease

14.3.4.4.2. Non-Pharmacological Management of Parkinson’s Disease

14.3.4.4.3. Management of Parkinson’s Disease using Dietary Supplements

 

14.3.4.5. BBB Penetrating Drugs for Parkinson’s Disease

14.3.4.6. Roots Analysis Perspective

 

15. LIKELY PARTNER ANALYSIS

15.1. Chapter Overview

15.2. Scope and Methodology

 

15.3. Potential Strategic Partners for Drug Development

15.3.1. Opportunities in North America

15.3.1.1. Most Likely Partners

15.3.1.2. Likely Partners

15.3.1.3. Less Likely Partners

 

15.3.2. Opportunities in Europe

15.3.2.1. Most Likely Partners

15.3.2.2. Likely Partners

15.3.2.3. Less Likely Partners

15.3.3. Opportunities in Asia-Pacific and Rest of the World

15.3.3.1. Most Likely Partners

15.3.3.2. Likely Partners

15.3.3.3. Less Likely Partners

 

16. MARKET FORECAST

16.1. Chapter Overview

16.2. Forecast Methodology and Key Assumptions

16.3. Overall BBB Penetration Technologies Market, 2020-2030

16.3.1. BBB Penetration Technologies Market: Contribution from Upfront Payments, 2020-2030

16.3.2. BBB Penetration Technologies Contribution from Milestone Payments, 2020-2030

 

16.4. Overall BBB Penetrating Drugs Market, 2020-2030

16.4.1. BBB Penetrating Drugs Market: Distribution by Type of Molecule

16.4.1.1. BBB Penetrating Drugs Market for Small Molecules, 2020-2030

16.4.1.2. BBB Penetrating Drugs Market for Biologics, 2020-2030

 

16.4.2. BBB Penetrating Drugs Market: Distribution by Target Disease Indication

16.4.2.1. BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030

16.4.2.2. BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030

16.4.2.3. BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030

16.4.2.4. BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030

 

16.4.3. BBB Penetrating Drugs Market: Distribution by Key Geographical Regions

16.4.3.1. BBB Penetrating Drugs Market in North America, 2020-2030

16.4.3.2. BBB Penetrating Drugs Market in Europe, 2020-2030

16.4.3.3. BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030

 

16.4.4. BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms

16.4.5. BBB Penetrating Drugs Market: Distribution by Leading Drug Developers

 

16.5.6. Drug-wise Sales Forecast

16.5.6.1. 2B3-101 / 2X-111 (2X Oncology)

16.5.6.1.1. Sales Forecast (USD Million)

16.5.6.1.2. Risk-Adjusted Market Opportunity (USD Million)

16.5.6.1.3. Net Present Value (USD Million)

16.5.6.1.4. Value Creation Analysis

 

16.5.6.2. AGT-181 (ArmaGen)

16.5.6.2.1. Sales Forecast (USD Million)

16.5.6.2.2. Risk-Adjusted Market Opportunity (USD Million)

16.5.6.2.3. Net Present Value (USD Million)

16.5.6.2.4. Value Creation Analysis

 

16.5.6.3. AGT-182 (ArmaGen)

16.5.6.3.1. Sales Forecast (USD Million)

16.5.6.3.2. Risk-Adjusted Market Opportunity (USD Million)

16.5.6.3.3. Net Present Value (USD Million)

16.5.6.3.4. Value Creation Analysis

 

16.5.6.4. ANG1005 (Angiochem)

16.5.6.4.1. Sales Forecast (USD Million)

16.5.6.4.2. Risk-Adjusted Market Opportunity (USD Million)

16.5.6.4.3. Net Present Value (USD Million)

16.5.6.4.4. Value Creation Analysis

 

16.5.6.5. JR-141 (JCR Pharmaceuticals)

16.5.6.5.1. Sales Forecast (USD Million)

16.5.6.5.2. Risk-Adjusted Market Opportunity (USD Million)

16.5.6.5.3. Net Present Value (USD Million)

16.5.6.5.4. Value Creation Analysis

 

17. CONCLUSION

17.1. Chapter Overview

17.2. Key Takeaways

 

18. EXECUTIVE INSIGHTS

18.1. Chapter Overview

18.2. Innovative California Biosciences International (ICBI)

18.2.1. Company Snapshot

18.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder

 

18.3. Ossianix

18.3.1. Company Snapshot

18.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder

 

18.4. 2-BBB

18.4.1. Company Snapshot

18.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder

 

18.5. ArmaGen

18.5.1. Company Snapshot

18.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer

 

18.6. biOasis Technologies

18.6.1. Company Snapshot

18.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer

 

18.7. Cyclenium Pharma

18.7.1. Company Snapshot

18.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer

 

18.8. Sagetis Biotech

18.8.1. Company Snapshot

18.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer

 

18.9. CarThera

18.9.1. Company Snapshot

18.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs

 

18.10. Vect-Horus

18.10.1. Company Snapshot

18.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development

 

18.11. Wyss Institute, Harvard University

18.11.1. Organization Snapshot

18.11.2. Interview Transcript: Kevin Kit Parker, Professor

 

19. APPENDIX I: TABULATED DATA

 

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com